Clinical trials in cellular immunotherapy for brain/CNS tumors

Expert Rev Neurother. 2013 Apr;13(4):405-24. doi: 10.1586/ern.13.23.


High-grade gliomas are the most common type of primary malignant brain/CNS tumor. There have been only modest advances in surgical techniques, radiotherapy and chemotherapy for high-grade gliomas over the past several decades. None of these have provided a major improvement in survival for patients. Recently, immunotherapy has been explored for the treatment of high-grade gliomas. Immunotherapy capitalizes on the specificity of the host immune system to selectively target tumor cells for destruction, while sparing normal brain parenchyma, thus making it a particularly attractive option. This article provides a comprehensive review of published clinical trials evaluating cellular immunotherapy in primary brain/CNS tumors.

Trial registration: NCT00045968 NCT01109095 NCT01454596.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms / therapy*
  • Central Nervous System Neoplasms / therapy*
  • Clinical Trials as Topic*
  • Glioma / therapy*
  • Humans
  • Immunotherapy / methods*

Associated data